[HTML][HTML] Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching …
M Zhuo, Q Zheng, J Zhao, M Wu, T An… - Chinese Journal of …, 2017 - ncbi.nlm.nih.gov
Objective Although superior clinical benefits of epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …
[HTML][HTML] Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching …
M Zhuo, Q Zheng, J Zhao, M Wu, T An, Y Wang, J Li… - Survival, 2017 - cjcrcn.org
Objective: Although superior clinical benefits of epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …
Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis
M Zhuo, Q Zheng, J Zhao, M Wu… - Chinese journal of …, 2017 - pubmed.ncbi.nlm.nih.gov
Objective Although superior clinical benefits of epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …
[PDF][PDF] Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching …
M Zhuo, Q Zheng, J Zhao, M Wu, T An, Y Wang, J Li… - article.cjcrcn.org
Objective: Although superior clinical benefits of epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …
Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis.
M Zhuo, Q Zheng, J Zhao, M Wu, T An… - Chinese Journal of …, 2017 - europepmc.org
Objective Although superior clinical benefits of epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …
[PDF][PDF] Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching …
M Zhuo, Q Zheng, J Zhao, M Wu, T An, Y Wang, J Li… - researchgate.net
Objective: Although superior clinical benefits of epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …
[引用][C] Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: A propensity score matching …
M Zhuo, J Zhao, M Wu, T An, Y Wang, J Li… - Chinese Journal of …, 2017 - elibrary.ru
ZHUO M. 1, ZHAO J. 1, WU M. 1, AN T. 1, WANG Y.* 1, LI J. 1, WANG S.* 1, ZHONG J. 1,
YANG X. 1, CHEN H. 1, JIA B. 1, DONG Z. 1, GAO E. 1, WANG J.* 1, WANG Z.* 1, ZHENG Q …
YANG X. 1, CHEN H. 1, JIA B. 1, DONG Z. 1, GAO E. 1, WANG J.* 1, WANG Z.* 1, ZHENG Q …
Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis.
M Zhuo, Q Zheng, J Zhao, M Wu, T An… - Chinese Journal of …, 2017 - europepmc.org
Objective Although superior clinical benefits of epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …
[PDF][PDF] Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching …
M Zhuo, Q Zheng, J Zhao, M Wu, T An, Y Wang, J Li… - cjcrcn.org
Objective: Although superior clinical benefits of epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …